Pfizer and Biontech announced today (Tuesday) that they have begun a clinical trial for the specific vaccine against Omicron.
The study will be conducted among 1,420 healthy adults between the ages of 18 and 55.
The study is divided into three groups: Participants in the first group will receive two doses of the existing Pfizer vaccine against Corona, at least 90 to 180 days before the study.
Next, they will receive one or two doses of the Omicron-specific vaccine.
Participants in the second group will receive three doses of Pfizer's existing vaccine, at least 90 to 180 days before the study.
They will then receive one dose of the Pfizer vaccine against Corona or the Omicron-specific vaccine.
CEO of Pfizer Burla: The lives of some 5,500 Israelis have been saved thanks to vaccines in the last four months
Participants in the third group will not receive a single dose of Pfizer's existing vaccine, and they will receive three doses of the Omicron-specific vaccine.
Katherine Jansen, senior vice president and head of vaccine research and development at Pfizer, said: "Recent studies and data from around the world indicate many hospitalizations following omicron, so we recognize the need to be prepared in case vaccine defenses fade over time, and to help deal with omicron in the future".
Pfizer CEO Albert Burla said last month that if a new vaccine against Omicron was required, it would be in the company's possession in March. A Pfizer spokesman confirmed that the company had already begun producing that vaccine.
Were we wrong?
Fixed!
If you found an error in the article, we'll be happy for you to share it with us